EOTT:GDF15: a potential therapeutic target for type 1 diabetes

Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas

Destruction of insulin-producing beta cells in the pancreas Approximately 40% of T1D cases reported globally are associated with human leukocyte antigen (HLA) gene polymorphisms; however, the recent increase in the number of T1D in children, coupled with a decrease in the frequency of HLA genotypes, suggests that Increased environmental stress is one reason

 GDF15 is a secreted cytokine with low sequence homology to TGF-β, but has been classified as a TGF-β family due to the presence of a unique cysteine-knot feature in the TGF-β family remote member of

Recently, interest in GDF15 has grown significantly due to multiple landmark studies independently identifying the glial cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL) receptor as the primary receptor for GDF15

GDF15 accelerates lipid oxidation and is thought to be an adjunct to AKT/ERK signaling, which contributes to the observed weight loss phenotype

Figure 1

Figure 1

Figure 1 Regulators and effectors of GDF15

Figure 1 Regulators and effectors of GDF15

Figure 2 illustrates the staging of T1D and the potential therapeutic role of GDF15

Figure 2 illustrates the staging of T1D and the potential therapeutic role of GDF15

GDF15: a potential therapeutic target for type 1 diabetes Leave a

comment here